Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Buy” by Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been assigned an average rating of “Buy” from the twelve analysts that are currently covering the company, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $53.64.

Several brokerages have recently commented on MIRM. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 9th. SVB Leerink reduced their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the company an “outperform” rating in a research note on Monday, June 17th. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th. Finally, JMP Securities upped their price target on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 18th.

Mirum Pharmaceuticals Trading Up 2.9 %

NASDAQ:MIRM opened at $32.05 on Friday. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $35.56. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -8.64 and a beta of 1.10. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31. The company’s 50 day moving average is $25.64 and its 200-day moving average is $27.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. The company had revenue of $69.22 million for the quarter, compared to the consensus estimate of $69.71 million. Equities analysts anticipate that Mirum Pharmaceuticals will post -1.42 EPS for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Mirum Pharmaceuticals news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Eric Bjerkholt acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was bought at an average cost of $24.80 per share, with a total value of $49,600.00. Following the acquisition, the chief financial officer now owns 14,000 shares in the company, valued at approximately $347,200. The disclosure for this purchase can be found here. 22.87% of the stock is owned by company insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its holdings in Mirum Pharmaceuticals by 34.2% during the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock valued at $69,470,000 after purchasing an additional 704,659 shares during the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in Mirum Pharmaceuticals by 64.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock valued at $4,090,000 after purchasing an additional 63,871 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Mirum Pharmaceuticals by 37.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock valued at $40,131,000 after purchasing an additional 432,824 shares during the last quarter. Affinity Asset Advisors LLC increased its position in Mirum Pharmaceuticals by 220.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 160,000 shares of the company’s stock worth $4,019,000 after buying an additional 110,000 shares during the period. Finally, William Blair Investment Management LLC increased its position in Mirum Pharmaceuticals by 0.9% during the 1st quarter. William Blair Investment Management LLC now owns 627,272 shares of the company’s stock worth $15,757,000 after buying an additional 5,494 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.